Literature DB >> 12922132

Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100.

Dante J Marciani1, Robert C Reynolds, Ashish K Pathak, Kyra Finley-Woodman, Richard D May.   

Abstract

Unfractionated GPI-0100 (UFGPI-0100) containing semi-synthetic derivatives of deacylated Quillaja saponins (DS saponins) modified at the glucuronic acid residue was resolved by reverse phase low-pressure liquid chromatography (RP-LPLC) into two fractions, RP18-1 and RP18-2, with different compositions and adjuvanticity. The fraction RP18-1 contained DS saponin adducts of N-dicyclohexylurea, and stimulated Th2 immunity with production of IgG1, while the RP18-2 fraction contained the dodecylamide derivatives of DS saponins and stimulated Th1 immunity with production of IgG2a, IFN-gamma, IL-2, and CTL. The strong immune stimulatory properties of RP18-2, relative to RP18-1, and the formation of RP18-1/RP18-2 mixed micelles may account for the effective stimulation of Th1 immunity by UFGPI-0100. UFGPI-0100 was free of acylated quillaja saponin components, including the more stable QS-7.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922132     DOI: 10.1016/s0264-410x(03)00298-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B.

Authors:  Dalia E Gaddis; Suzanne M Michalek; Jannet Katz
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

2.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

3.  Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.

Authors:  Ka Ian Tam; Michael R Roner
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

4.  Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors:  Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

5.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

6.  Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.

Authors:  Pengfei Wang; Dattatray A Devalankar; Qipu Dai; Ping Zhang; Suzanne M Michalek
Journal:  J Org Chem       Date:  2016-10-13       Impact factor: 4.354

7.  Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

Authors:  Axel T Lehrer; Teri-Ann S Wong; Michael M Lieberman; Lisa Johns; Liana Medina; Friederike Feldmann; Heinz Feldmann; Andrea Marzi
Journal:  Vaccine       Date:  2019-07-16       Impact factor: 3.641

8.  Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Authors:  Balasubramanyam Karanam; Ratish Gambhira; Shiwen Peng; Subhashini Jagu; Dae-Jin Kim; Gary W Ketner; Peter L Stern; Robert J Adams; Richard B S Roden
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

9.  Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.

Authors:  Michael M Lieberman; Vivek R Nerurkar; Haiyan Luo; Bruce Cropp; Ricardo Carrion; Melissa de la Garza; Beth-Ann Coller; David Clements; Steven Ogata; Teri Wong; Tim Martyak; Carolyn Weeks-Levy
Journal:  Clin Vaccine Immunol       Date:  2009-07-29

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.